The best thing about the stock market is that you can make money in�either direction. Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long haul. According to hedge fund institution Blackstar Funds, even with dividends�included, between 1983 and 2006, 64% of stocks underperformed the�Russell 3000, a broad-scope market index.
A large influx of short-sellers shouldn't be a condemning factor for any company, but it could be a red flag from traders that something is off. Let's look at three companies that have seen a rapid increase in the number of shares sold short and see whether traders are blowing smoke or if their worry has some merit.
Company
Short Increase Sept. 30 to Oct. 15
Short Shares as a % of Float
CVS Caremark (NYSE: CVS )
Top 5 Airline Stocks To Watch For 2015: Haemonetics Corp (HAE)
Haemonetics Corporation, incorporated on August 29, 1985, is a healthcare company engaged in providing blood management solutions to its customers. The Company�� portfolio of integrated devices, information management and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world.The Company serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. On April 30, 2013, the Company acquired of certain assets of Hemerus LLC.
The Company helps its customers create and maintain a safe and efficient blood supply chain. Specifically, it develops and markets a wide range of systems used with plasma and blood donors that collect and process blood into its components using both manual and automated methods. It also develops and markets a variety of systems to hospitals that automate the cleaning and reinfusion of a surgical patient's blood during surgery, automate the tracking and distribution of blood in the hospital, and enhance blood diagnostics. The Company sells information technology platforms to promote efficient and compliant operations for all of its customer groups. The Company provides consulting services to reduce costs and improve operating efficiencies in blood management. . Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does.
Plasma
Human plasma is collected and processed by bio-ph! armaceutical companies into therapeutic and diagnostic products that aid in the treatment of immune diseases and coagulation disorders. While plasma is also used to aid patients with extreme blood loss, such as trauma victims, this portion of its business solely focuses on plasma's pharmaceutical uses. Automated plasma collection technology allows for the safe and efficient collection of plasma. The Company manufactures and market plasma collection devices and respective disposables, but do not make plasma-derived pharmaceuticals.
The Company�� portfolio of products and services is designed to support multiple facets of plasma collector operations. The Company with its PCS brand automated plasma collection technology, more plasma can be collected during any one donation event because the other blood components are returned to the donor through the sterile disposable sets used for the plasma donation procedure. The Company offers one stop shopping to its plasma collection customers, enabling them to source from them the full range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions. It also offers a robust portfolio of integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain. Its products automate the donor interview and qualification process; streamline the workflow process in the plasma center; provide the controls necessary to evaluate donor suitability; determine the ability to release units collected; and manage unit distribution.
Blood Center
The Company offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products.The Company markets the MCS (Multicomponent Collection System) brand apheresis equipment which is designed to collect specific blood components integrated from the donor. Utilizing t! he MCS au! tomated platelet collection protocols, blood centers collect one or more therapeutic doses of platelets during a single donation by a volunteer blood donor. The MCS two-unit protocol or double red cell collection device helps blood collectors optimize the collection of red cells by automating the blood separation function, eliminating the need for laboratory processing, and enabling the collection of two units of red cells from a single donor thus maximizing the amount of red cells collected per eligible donor and helping to mitigate red cell shortages in countries where this problem exists. Blood collectors can also use the MCS system to collect one unit of red cells and a jumbo (double) unit of plasma, or one unit of red cells and one unit of platelets from a single donor. The MCS plasma protocol providing the possibility to collect 600-800ml of plasma for transfusion to patients or for pharmaceutical industry use completes the comprehensive portfolio of different blood component collection options on this device.
The Company offers a portfolio of products for manual whole blood collection and processing. Haemonetics' portfolio of disposable whole blood collection and component storage sets offer flexibility in collecting a unit of whole blood and the subsequent production and storage of the red blood cell, platelet, and/or plasma products, including options for in-line or dockable filters for leukoreduction of any blood component. In addition Acrodose product line provides a closed system for the pooling, storage, and bacteria testing of leukoreduced whole blood derived platelet concentrates, an Acrodose Platelet, that is transfusion ready for the hospital. Use of Acrodose platelets lowers hospital handling costs by eliminating the need for pooling and bacteria testing at the hospital.
The Company with ACP(Automated Cell Processor) brand offers a small bench-top solution to automate the washing and freezing of red cell components in the lab. The automated red cell was! hing proc! edure removes plasma proteins within the red cell units to provide a safer product for transfusion to frequently transfused patients, neonates, or patients with a history of transfusion reactions. The automated glycerolization and deglycerolization steps are required to prepare red cells for frozen storage. Freezing the red cell units can expand the shelf life of these products up to 10 years. Customers utilize this technology to implement strategic red cell inventories for catastrophe cases, storage of rare blood types, or enhanced inventory management.
Hospital
The Company offers a range of blood management solutions that significantly improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing it efficiently and correctly. Its products and integrated solution platforms help hospitals optimize performance of blood acquisition, storage, and distribution.The Company�� TEG Thrombelastograph Hemostasis Analyzer system is a blood diagnostic instrument that measures a patient's hemostasis or the ability to form and maintain blood clots.
The Cell Saver system is a surgical blood salvage system targeted to procedures that involve rapid, high-volume blood loss, such as cardiovascular surgeries. It has become the standard of care for high blood-loss surgeries. During the year ended December 31,2012, the Company launched the Cell Saver Elite system, which is autotransfusion option to minimize allogeneic blood use for surgeries with medium to high blood loss. The OrthoPAT surgical blood salvage system is targeted to procedures, such as orthopedic, that involve slower, lower volume blood loss that often occurs well after surgery. The cardioPAT system is a surgical blood salvage system targeted to open heart surgeries when there is less blood loss during surgery, but where the blood loss continues post-surgery. These systems are designed to remain with the patient following surgery, to recover blood and produce a washed red cell produ! ct for au! totransfusion. Their Quick-Connect feature permits customers to utilize the blood processing set selectively, depending on the patient's need.
The Company�� IMPACT Online Web-based software platform, which monitors and measures improvements in a hospital�� blood management practices, provides hospitals with a baseline view of their blood management metrics and helps monitor transfusion rates. Business consulting solutions are offered to support process and blood management efforts. It also provides blood management assessment tools to hospitals that enables its customers to monitor their progress in order to continually improve their blood management performance.
Software Solutions
The Companby has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. For its plasma customers, it also provides information technology platforms for managing donors and information associated with the collection of plasma products within fractionation facilities.
The Company�� software solutions , including information technology platforms and consulting services can be combined with its devices and sold through its plasma, blood center, and hospital sales forces. The Company�� software products help hospitals track and safely deliver stored blood products. SafeTrace Tx is its software solution that helps manage blood product inventory, perform patient cross-matching, and manage transfusions. In addition, its BloodTrack suite of solutions manages tracking and control of blood products from the hospital blood center through to transfusion to the patient. Smart refrigerators located in or near operating suites, emergency rooms, and other parts of the hospital dispense blood units with secure control and autom! ated trac! eability for efficient documentation. With its offerings, hospitals are better able to manage processes across the blood supply chain and identify increased opportunities to reduce costs and enhance processes. Its software solutions, such as its SafeTrace and El Dorado Donor donation and blood unit management systems, span blood center operations and automate and track operations from the recruitment of the blood donor to the disposition of the blood product. Its Hemasphere software solution provides support for more efficient blood drive planning, and Donor Doc and e-Donor software help to improve recruitment and retention.
The Company competes with Fenwal, Inc., Terumo BCT ,Caridian BCT, Rotem, MAK Systems, Mediware, MacoPharma , Medtronic, Fresenius, Sunquest Information Systems and Sorin Biomedica.
Advisors' Opinion:- [By Lisa Levin]
Haemonetics (NYSE: HAE) shares fell 8.57% to reach a new 52-week low of $30.40 after the company Q4 adjusted earnings of $0.46 per share on revenue of $241.10 million. The company's board also announced a $100 million share buyback program.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Haemonetics (NYSE: HAE ) , whose recent revenue and earnings are plotted below. - [By Holly LaFon]
Haemonetics (HAE) is the market leader in blood management products for collection centers and hospitals. The company's equipment and related consumables allow collection centers to separate blood into the components of plasma, red cells and white cells. Hospital-based products include blood diagnostics, devices to salvage patient blood during surgery and software to manage blood supply. Earnings temporarily declined due to two product quality issues that management of Haemonetics has stated have been remedied. In our opinion, earnings growth may be expected to accelerate in the next few years as Haemonetics rolls out its automated whole blood collection solution to collection centers. Relative to the existing manual process, the company's automated solution speeds up the collection process and reduces discard rates. Cost and efficiency gains become more important to collection centers as hospitals better manage their blood supply. We believe the company is a compelling value at 12x our $3.50 estimate of earnings power.
Hot Long Term Companies For 2014: Ceragon Networks Ltd.(CRNT)
Ceragon Networks Ltd. offers wireless backhaul solutions that enable cellular operators and other wireless service providers to deliver voice and data services. Its wireless backhaul solutions use microwave technology to transfer large amounts of telecommunication traffic between base stations and the core of the service provider?s network. The company offers Internet protocol (IP) based FibeAir IP-10E/IP-MAX2, a high-capacity Ethernet that is used in wireless backhaul for carriers, private networks, and metro area networks; FibeAir IP-10G/IP-MAX2, a high-capacity multi-service, which is used in wireless backhaul for carriers and private networks; FibeAir 2000/4800, an unlicensed multi-service for private networks and business access; FibeAir/1500R, a high-capacity SDH/SONET for wireless backhaul and metro area networks; and FibeAir 3200T, a high-capacity circuit-switched TDM for wireless backhaul and long distance networks. It also provides advanced pure IP/Ethernet solu tions to wireless broadband service providers, as well as to businesses and public institutions that operate their own private communications networks. In addition, the company offers turnkey project services, including network and radio planning, site survey, solutions development, installation, maintenance, and training services. It sells its products through various channels, including direct sales, original equipment manufacturers, resellers, distributors, and system integrators in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company was formerly known as Giganet Ltd. and changed its name to Ceragon Networks Ltd. in September 2000. Ceragon Networks Ltd. was founded in 1996 and is headquartered in Tel Aviv, Israel.
Advisors' Opinion:- [By Peter Graham]
The third quarter 2014�earnings report for network communication platform maker�Ubiquiti Networks Inc (NASDAQ: UBNT), a peer of small cap stocks�Aviat Networks Inc (NASDAQ: AVNW), Ceragon Networks Ltd (NASDAQ: CRNT) and�DragonWave, Inc (NASDAQ: DRWI), is due out after the market closes on Thursday with shares already trending upwards as they closed 4.08% higher on Tuesday. Aside from the Ubiquiti Networks earnings report, it should be said that Aviat Networks Inc reported earnings yesterday after the market closed (shares were sinking hard in after hours trading); Ceragon Networks Ltd will report earnings before the market opens on Thursday; and DragonWave, Inc is scheduled to report after the market closes next Wednesday. So it�� a busy week for network communications stocks.
Hot Long Term Companies For 2014: Green Technology Solutions Inc (GTSO)
Green Technology Solutions Inc (GTSO), incorporated on February 22, 1991, is in the business of identifying and acquiring rights in early stage, green technologies, with the plan to develop these technologies into marketable products. The Company has identified several technology endeavors.
As of December 31, 2011, the Company has identified the advancement of mining technologies, with an emphasis on rare earth and precious metals mining applications, the development of additional markets for existing paint products that are being marketed in the United States, and smart grid technology. GTSO has also identified additional joint venture in China and South America.
Advisors' Opinion:- [By CRWE]
Today, GTSO surged (+13.33%) up +0.0040 at $.0340 with�43,370 shares in play thus far (ref. google finance Delayed: 12:18PM EDT September 20, 2013).
With heightened tensions in the Middle East expected to push oil prices to their highest levels in years, Green Technology Solutions, Inc. (OTCBB: GTSO) is aggressively looking into the more economical option of advanced biofuels.
A potential military strike by the United States against Syria is expected to elevate oil and gasoline prices to unprecedented heights. GTSO, an environmentally conscious company with an ongoing interest in delivering ��reen friendly��solutions to a global market, is exploring the option of comparatively inexpensive biofuels, assets that have the potential to figure prominently once again amidst current global chaos.
- [By CRWE]
Today, GTSO surged (+0.32%) up +0.0001 at $.0309 with 12,300 shares in movement thus far (ref. google finance Delayed: 10:31AM EDT June 20, 2013).
Green Technology Solutions, Inc. previously reported it has finalized a joint venture agreement with leading Latin American e-waste recycler Chilerecicla.
Latin America is a key emerging market in the booming the global e-waste recycling and reuse services industry, which Transparency Market Research predicts accounted for more than $9 billion in 2012. The firm expects the worldwide e-waste market to reach $18 billion in 2017, growing at a compound annual growth rate of 13.2 percent from 2012 to 2017.
Hot Long Term Companies For 2014: Village Super Market Inc.(VLGEA)
Village Super Market, Inc., together with its subsidiaries, operates a chain of supermarkets in the United States. The company?s superstores feature specialty departments, such as home meal replacement, on-site bakery, and expanded delicatessen that includes prepared food, natural and organic food, ethnic and international food, seafood sections, as well as pharmacies and salad bars. Its superstores also offer non-food items, including cut flowers, health and beauty aids, greeting cards, and small appliances. As of December 16, 2011, the company operated a chain of 28 supermarkets under the ShopRite name in New Jersey, Maryland, and eastern Pennsylvania. Village Super Market, Inc. was founded in 1933 and is based in Springfield, New Jersey.
Advisors' Opinion:- [By Geoff Gannon]
Line up the return on capital lines ��for the last 10 years ��for Arden, Village (VLGEA), Weis, Harris Teeter (HTSI), and Kroger and you��l see that the grocer this analyst thinks is unique clearly isn��. Other grocers earn their cost of capital. They just aren�� as well known.
- [By Geoff Gannon]
Okay. So my point is just that a business is a business ��it�� not an industry. Just because a company is categorized in an industry doesn�� mean it works like the other companies in the industry. For example, Amazon (AMZN) and Best Buy (BBY) and Walgreens (WAG) and Village Supermarket (VLGEA) are all retailers. But they are all really, really different retailers. Technology changes have vastly different influences on them. They have completely different business models. They are actually trying to do totally different things. And you would analyze them ��especially starting with customer habits ��totally differently.
- [By Geoff Gannon] the last 10 years ��population growth, inflation, and real output per person growth has been so low it�� hard to tell the difference between companies growing at the rate of inflation, along with the population, or along with the economy.
You have to squint really hard to see any difference in the revenue growth records of DNB, Chuck E. Cheese, and Village.
This will not be true in all countries and at all times.
A literally no growth company like Earthlink is actually shrinking. It just happens to look like it�� staying perfectly flat because inflation is hiding the company�� real decay rate. In real terms, the company has been shrinking by about 3% a year for the last 10 years. So, Earthlink is not a no growth company. It�� shrinking.
That�� a bad sign. And, frankly, I don�� know how to value Earthlink. You would need to evaluate it as a turnaround or something ��not as a business that�� simplly stuck in place. I don�� know how to do that.
So, Earhtlink goes into the ��oo hard��pile.
Dun & Bradstreet and CEC Entertainment are actual no growth businesses. This is hidden by their constant share buy backs. So, if you look at their earnings per share growth they look kind of like Peter Lynch�� idea of a ��low growth��company or even a ��talwart�� They aren��. They��e no growth businesses.
The same is pretty much true with Village Supermarket. Although this is complicated. The nature of their business ��high volume, low cost groceries ��means they can appear to be a no growth business when they are actually just keeping prices down and increasing volume. You would need to check their sales numbers more carefully. Grocery stores often discuss inflation in their annual reports. Village Supermarket always does this.
(The annual report is Exhibit 13 of the 10-K at EDGAR).
So, in reality, Village Supermarket may be a slow grower, while CEC Entertainment and Dun & Bradstreet
- [By Geoff Gannon] strong>J&J Snack Foods (JJSF)
Check out the performance numbers on those three stocks over the last 10-13 years (I bought them at different times). You��l notice that if I just never sold those stocks I wouldn�� need to do anything else. Those three stocks would��e made a fine portfolio for the next decade or so.
Well, I did sell those stocks. And I did a lot else. And some of it worked very well and some of it worked very badly. But, almost without fail, the net result was never better than what would have happened if I�� kept those three stocks.
That�� not an accident. It took me a very, very long time to buy stocks when I was a kid. I bought six stocks in my first five years as an investor. That�� not quite a 20 punches approach ��but it�� pretty close.
Why did I only buy one stock a year?
Because I didn�� know anything about stocks. And I didn�� think I knew anything about stocks.
My investment style was formed from a combination of extreme ignorance and extreme confidence. I was totally ignorant about stocks. And I was totally confident that I could learn all I needed to know about the stocks I needed to know about.
That combination led to focusing on a few very specific stocks. Stocks I was comfortable with.
When I was 14, there were only two places my money went. Into my brokerage account. Or into video games. So it�� not a surprise I bought Activision. At the time the video game industry had a much clearer future than it does today. And there was no better CEO of a video game company than Bobby Kotick. The balance sheet was pristine. When you backed out cash, the stock was cheap relative to sales. I looked at everything I could about video game companies and I decided sales were pretty profitable and pretty cash generative in this industry. All you needed was sensible capital allocation. All you needed was management that was going to run the place like a business. And I thought you h
Hot Long Term Companies For 2014: NPS Pharmaceuticals Inc.(NPSP)
NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company?s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.
Advisors' Opinion:- [By Keith Speights]
Although there is no cure for SBS, three drugs have been approved in the U.S. for treating the disease. The most recently approved treatment is Gattex. NPS Pharmaceuticals (NASDAQ: NPSP ) received Food and Drug Administration approval for the drug in late 2012. Gattex works by spurring growth in mucous membranes involved in absorption and secretion.
- [By Ben Levisohn]
Markey rates the stock a Buy with an $11 price target. Shares of MannKind have jumped 14% to $7.85 today. The SPDR Biotech ETF (XBI) has gained 0.7% to $119.85 today, while Alnylam Pharmaceuticals (ALNY) has gained 1% to $49.05, NPS Pharmaceuticals (NPSP) has fallen 4.1% to $23.56, and InterMune (ITMN) has risen 2.6% to $14.89.
- [By Jon C. Ogg]
NPS Pharmaceuticals Inc. (NASDAQ: NPSP) is among the best revenue growth possibilities for biotech in 2014. The company’s revenue�growth is expected to be 71%. We would caution that the consensus analyst price target of $37 implies more than 40% upside, but what our readers need to know is that this stock has been an incredibly volatile one. With shares around $25, it has a 52-week range of $7.35 to $35.72.
Hot Long Term Companies For 2014: American Heritage International Inc (AHII)
American Heritage International Inc., formerly Cumberland Hills Ltd., incorporated on January 19, 2010, intends to focus on electronic cigarette. The Company�� product includes American Heritage, American One, American Freedom, American Nights, American Standard and Smoking Alternative Gums and Mints.
The Company�� initial and primary line will be the American Heritage line. American One is a disposable Electronic Cigarette, good for over 500 draws, about the equivalent of over two packs of traditional cigarettes. American Freedom will be the brand name for its Nicotine-Free line of Electronic Cigarettes. American Nights will be a product line targeted to the young adult market of social smokers. Smoking Alternative products will include gums, and mints.
Advisors' Opinion:- [By John Udovich]
Small cap electronic cigarette stocks Vapor Corp (OTCMKTS: VPCO), Smokefree Innotec�(OTCMKTS: SFIO), Hop-On Inc (OTCMKTS: HPNN) and American Heritage International Inc (OTCBB: AHII) are what�� left of the e-Cig market not controlled by ��ig Tobacco��and at least one of these stocks is positioning itself or its technology to exploit opportunities in marijuana or cannabis. Last year, industry experts were saying that�US retail sales of e-cigarettes could reach $1 billion for the year or�1% of the country's cigarette market but twice that of 2012�as sales go off the Internet and into more mainstream retailers. Moreover, they are being positioned as a ��ealthier��alternative to smoking (albeit some places have already extended their smoking bans to cover the devices). It should be stated that electronic cigarettes look just like traditional cigarettes and are usually comprised of three functional components:
No comments:
Post a Comment